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A B S T R A C T
Progress of the disease and prolonged treatment with antibiotics or immunosuppressive agents makes tu-
berculosis patients susceptible to fungal infections. This study aimed to determine the prevalence of pulmonary
Aspergillus coinfection among patients with pulmonary tuberculosis in Asia and Africa.
The present review of cross-sectional studies was conducted on the prevalence of pulmonary Aspergillus
coinfection among patients with pulmonary tuberculosis according to the PRISMA Protocol. Literatures pub-
lished online in English from January 2001 to March 2019 via key databases such as Web of Science, MEDLINE,
PubMed, Scopus, and Cochrane Library were searched. The used MeSH and non-MeSH keywords were; “pul-
monary fungal”, “pulmonary coinfection”, OR “Pulmonary mycosis”, “pulmonary fungal infections/agents”, OR
“Polymicrobial infection”, OR “Secondary infection”, OR “Mixed infections”, “pulmonary aspergillosis”, “fungi
coinfection”, “Fungal co-colonization”, AND “pulmonary tuberculosis”, OR “pulmonary TB”, AND “Asia” AND
“Africa”. Finally, data analyzed using Comprehensive Meta-Analysis software (CMA).
The combined Aspergillus coinfection among patients with pulmonary tuberculosis was 15.4% (95% CI:
11.4–20.5), Q = 105.8 and Z = 9.57 in Asia and Africa. The most frequency of Aspergillus spp. was related to A.
fumigatus with a combined prevalence of 57.6%. Most of the studies included in the present review showed a
higher Aspergillus coinfection in the age group of 40 years and higher. Also, the existence of a correlation be-
tween increasing age and Aspergillus coinfection was reported (p < 0.05).
The present review showed a high combined Aspergillus coinfection among patients with pulmonary tu-
berculosis in Asia and Africa. Also, amongst the Aspergillus spp., the most frequent was related to A. fumigatus.
1. Introduction
Progress of the disease and prolonged treatment with antibiotics or
immunosuppressive agents makes tuberculosis patients im-
munocompromised and hence become susceptible to fungal infections
[1]. When host defense is decreased, these unrecognized opportunistic
fungi may affect the trend of disease or may even become fatal [2].
Coinfection is defined as the simultaneous presence of 2 or more
infections, which may increase the severity and duration of one or both
[3]. Pulmonary aspergillosis co-infection includes simultaneous infec-
tion of a host's lungs with Aspergillus spp., and Mycobacterium tubercu-
losis that cause more complications [4]. One cannot over-emphasize the
point that the incidence and prevalence of respiratory fungal infections
in many developing countries have remained largely unexplored and
neglected. This has led to a widespread erroneous impression about
their true public health importance [5]. Considering its devastating
effects like other respiratory infections, this neglect has to be seen as a
major call for concern. As reported by the Centers for Disease Control
and Prevention (CDC), the mortality associated with Invasive Re-
spiratory Aspergillosis (IRA) has increased by 35.7% since 1980 with
the mortality of untreated IRA being nearly 100% [6]. On the other
hand, the Candida also is the most commonly isolated fungal pathogen
and may cause severe secondary infections in the immunocompromised
population, including tuberculosis patients [1]. Also, acquired immune
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deficiency syndrome (AIDS) and immune deficiency are developing
worldwide. Since opportunistic mycoses are a serious threat to such
patients, it is anticipated that these infections may break out in epi-
demic proportions under suitable circumstances [7]. In comparison to
HIV non-infected individuals, the human immunodeficiency viruses
(HIV) infected individuals are more 10 times susceptible to developing
tuberculosis (TB). Fungal pulmonary infections often precede the ap-
pearance of other opportunistic infections, but frequently co-exist with
other pathogens [8]. Many physicians missed fungal pulmonary infec-
tion because it does not show specific clinical manifestations and
usually hindered by other diseases like tuberculosis and cause high
rates of morbidity and mortality. Therefore, there is a critical need for
proper diagnosis of the opportunistic fungal pathogen especially in
tuberculosis patients [9].
The main predisposing factor is the forming of a preexisting lung
cavity secondary to tuberculosis [10]. A precondition for the pleural
aspergillosis is the previously damage or destruction of lung or pleura
through active tuberculosis [11]. Aspergillus species cause a serious
pathologic condition (Aspergillosis) which is chiefly observed in im-
munocompromised people. Infection caused by Aspergillus can lead a
wide spectrum of complications with radiological and pathologic fea-
tures mimicking those of TB [12].
Studies are needed to define populations at high risk of these in-
fections who might benefit from targeted antifungal and antibacterial
chemoprophylaxis which remains the most promising of the potential
preventive strategies [13]. Considering the importance of Aspergillus
species and their coinfection with tuberculosis, and the lack of a com-
prehensive review in this regard, we performed a systematic review and
meta-analysis to determine the Aspergillus coinfection among patients
with pulmonary tuberculosis using summarizing data identified in the
published literature.
2. Materials and methods
2.1. Search strategy
We conducted a systematic search for cross-sectional studies con-
sidered the Aspergillus coinfection among patients with pulmonary
tuberculosis according to the PRISMA directions published from
January 2001 to March 2019 and indexed in international electronic
databases. Studies published online in the English language were se-
lected from international databases (Google Scholar, PubMed,
MEDLINE, Scopus, Cochrane Library, ScienceDirect, and Web of
Science). The search was performed by AK and AS combining the fol-
lowing Medical subject headings (MeSH) and non‐MeSH keywords;
“pulmonary fungal”, “pulmonary coinfection”, OR “Pulmonary my-
cosis”, “pulmonary fungal infections/agents”, OR “Polymicrobial in-
fection”, OR “Secondary infection”, OR “Mixed infections”, “pulmonary
aspergillosis”, “fungi coinfection”, “Fungal co-colonization”, AND
“pulmonary tuberculosis”, OR “pulmonary TB”, AND “Asia” AND
“Africa”. We checked the reference list of retrieved relevant articles to
find more studies.
2.1.1. Study eligibility criteria
The inclusion criteria were a) original studies with cross-sectional
design; b) studies considered pulmonary Aspergillus coinfection with
pulmonary tuberculosis. We included adults, children and other popu-
lation other than HIV- infected people and cancer patients.
Also, studies that did not address this subject, articles published
before 2001, commentaries, abstracts, case series, case reports, meeting
reports, letters to editor, congress articles, editorials, literatures with
illegibility in data reporting, articles reported in languages other than
English, duplicate publication of the same article, review literatures,
meta-analysis/systematic, and narrative reviews were excluded. Titles
and abstracts of studies were reviewed independently by two reviewers
(AK, AS) according to the eligibility criteria. Obvious discrepancies
about the inclusion of studies were discussed with the third author
(MHF).
2.2. Quality assessment
The quality of the studies included in the present review was eval-
uated by the criteria stated in Critical Appraisal Skills Programmed
checklists (www.casp-UK). Several questions were designed for each
study. If the relevant data was listed, the answer was scored as ‘yes’. If
there was any doubt, or data was not defined in the study, that question
was determined as ‘no’ or ‘can't tell’. studies categorized as ‘strong’,
‘intermediate’, or ‘weak’ according to the scoring system of the number
of questions scored as ‘yes’ [14]. Finally, studies with weak quality
excluded from the present review (File 1).
2.3. Data extraction
Two investigators (AK, AS) extracted the data {The first author's full
name, Year of publication, Location (country), Sample size, Coinfection,
Detection Methods (Molecular and Phenotypic)} from relevant studies.
Furthermore, the extracted data were matched and inconsistencies be-
tween reviewers were discussed to reach an agreement.
2.4. Correlation between pulmonary Aspergillus coinfection and
characteristics of participants and risk factors
The correlation between pulmonary Aspergillus coinfection and
Characteristics of patients such as age and genus, also, risk factors in-
cluding alcohol consumption, body mass index (BMI), smoking, and
diabetes mellitus (DM) were investigated.
2.5. Statistical analysis
The random-effects model was used to calculate the crude pre-
valence and its corresponding 95% confidence interval (CI). Statistical
heterogeneity between included studies was estimated using Cochran's
Q test and I2 statistic [15]. Substantial heterogeneity exists when I2
exceeds 50% or p-value for the Cochran's Q test was< 0.05 [16]. We
also used the subgroup analysis and Meta-regression to detect find
possible sources of heterogeneity [17]. To detect the potential pub-
lication bias, Egger's regression asymmetry test was used; furthermore,
the publication bias was checked using the funnel plot. The analyses
were performed using comprehensive meta-analysis software (CMA)
(Version 3.3.070). Two‐tailed p values equal or less than 0.05 was
considered as statistically significant.
3. Results
3.1. Study selection
Overall, 857 publications identified through online literature
searching and manual searching, of which 324 were duplicates, ab-
stracts, and titles of 533 articles were screened. Then, 360 were re-
moved based on the abstracts and titles searching. Next, 173 studies
included for full texts screening. Of these, 155 articles were excluded
for the following reasons: case report, data missing, unclear data, no
reporting coinfection, review studies, letters, meetings, studies in non-
pulmonary tuberculosis cases, studies published other than English.
Then, 18 articles included for qualitative assessment. A study excluded
owing to poor quality. Finally, 17 studies included in the quantitative
synthesis.
3.2. Characteristics of included studies
All the 17 selected studies were cross-sectional published between
January 2001 and March 2019. All studies conducted in third world
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countries and developing countries, especially Asian populations. Of
which, 9 from India, 3 from Iran, 2 from Cameroon, and remaining
were from Kenya, Iraq, and Egypt. All studies had recruited both men
and women, all precipitants (2868 people) were TB positive. All studies
showed the Aspergillus coinfection in pulmonary tuberculosis patients.
Aspergillus coinfection was varied between 3.7 and 33.3%. Sputum and
BAL samples were used for diagnosis of TB. Blood, sputum, and BAL
specimens were used for diagnosis of Aspergillus spp. Among studies,
one used a molecular method for detection of tuberculosis and
Aspergillus infections and remaining used of phenotypic methods. These
methods were; AFB analysis-Direct microscopy-Culture, Gram stain,
KOH Mount (KOH Preparation, Ziehl-Neelsen technique, Molecular
Assay, Sugar fermentation tests, Molecular identification of sequenced
ITS-18S rRNA genes, Microarray, ELISA, Dot Blot, and Agar gel diffu-
sion. A summary of the study characteristics is provided in Table 1 (see
Fig. 1).
3.3. Overall effects
Table 2 and Fig. 2 show that the combined prevalence of Aspergillus
coinfection among patients with pulmonary tuberculosis in Asia and
Africa was 15.4% (95% CI: 11.4–20.5), Q = 105.8 and Z = 9.57,
I2 = 84.8. The combined prevalence of Aspergillus coinfection among
patients with pulmonary tuberculosis in Asia was 14.7% (95% CI:
10.5–20.4), Q = 82.4 and Z = 8.78, I2 = 85.4. The pooled prevalence
of Aspergillus coinfection among patients with pulmonary tuberculosis
in Africa was 17.7% (95% CI: 7.7–35.8), Q = 21.5 and Z = 3.16,
I2 = 86.
3.3.1. Overall effects of Aspergillus species
The most frequency of Aspergillus spp. was related to A. fumigatus
with a combined prevalence of 57.6% (95% CI: 40.1–73.3), Q = 69.7
and Z = 0.84. Also, the combined prevalence of Aspergillus flavus, and
Aspergillus niger were 27.2% (95% CI: 19.3–36.7), and 33.8% (95% CI:
28.8–39.3), respectively. Other information of Aspergillus spp. is ab-
stracted in Table 3.
Table 1
Characteristics of studies included in the present review.
Author Time of Study Publication (Year) Location (Country) Sample Sizea Coinfection(n) Mean age Gender (%) Detection Methods
Male female Molecular Phenotypic1
Shahid [30] – 2001 India 20 5 46.3 + 12.4 – – – +
Kurhadi [31] – 2002 India 57 14 – – – – +
Bansod [32] 2002–2003 2008 India 1357 165 35 52 48 – +
Njunda [7] 2010–2011 2012 Cameroon 27 9 36.5 ± 17.16 49.6 50.4 – +
Osman [19] – 2013 Egypt 50 12 45 72 28 +2 –
Mwaura [33] 2009 2013 Kenya 172 9 – – – – +
Jabbari Amiri [34] 2014 2015 Iran 25 10 – +
Bhutia [35] 2013–2014 2015 India 14 2 50 59.5 40.5 – +
Mathavi [21] – 2015 India 107 17 – – – – +
Yadu [36] 2006–2007 2015 India 100 11 38.03 64 36 – +
Njunda [37] 2014 2015 Cameroon 44 9 34 54.5 45.5 – +
Jabbari amiri [38] 2006–2016 2016 Iran 430 16 – +
Babita [39] 2011–2012 2016 India 75 10 – – – – +
Astekar [18] – 2016 India 60 3 – – +
Aldorkee [40] 2012–2014 2017 Iraq 100 26 40.1 ± 10.8 65 35 – +
Jabbari Amiri [29] 2007–2017 2018 Iran 130 10 48 ± 1.8 70 30 – +
Bin Najeeb1 [41] 2015 2019 India 100 24 40 ± 10 73 27 – +
a People who were positive for tuberculosis.
Table 2
Pooled Aspergilus coinfection in pulmonary TB patients based on location (continent).
Overall Number of studies Heterogeneity test Egger's test Random model
Prevalence (95% CI) (%) Z P Q P I2 T P
Coinfection (Total) 17 15.4 (11.4–20.5) 9.57 0.000 105.8 0.00 84.8 0.8 0.4
Coinfection (Asia) 13 14.7 (10.5–20.4) 8.78 0.000 82.4 0.00 85.4 0.59 0.56
Coinfection (Africa) 4 17.7 (7.7–35.8) 3.16 0.002 21.5 0.000 86 0.79 0.50
Fig. 1. Flow diagram of inclusion process of selected studies.
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3.4. Sources of heterogeneity
Funnel plot did not show any publication bias (Fig. 3), also, the
Egger's linear regression was used to further reveal publication bias.
However, the results of Egger's linear regression revealed no publica-
tion bias (P = 0.0).
3.4.1. Specific subgroup analysis
To find possible sources of heterogeneity, subgroup analysis con-
ducted based on location (Asia, and Africa) and gender (Male, and
Female). The data abstracted in Fig. 4 didn't show strong evidence that
location (Asia, and Africa) was associated with variation in the esti-
mates. The heterogeneity was significant within groups (Q
test = 103.9, P = 0.00); but between-study heterogeneity was not
significant (Q test = 1.89, P < 0.16). Also, the heterogeneity was
significant for male (Q test, P = 0.00, I2 = 82.2%); also, it was sig-
nificant for female (Q test, P = 0.00, I2 = 82.6%) as well as for studies
that reported the data for both genders together (Q test, P = 0.00,
I2 = 89.1%). So, the heterogeneity was significant within groups (Q
test = 91.1, P = 0.00); but between-study heterogeneity was not
significant (Q test = 66.2, P < 0.00).
3.4.2. Meta-regression
Also, alongside with subgroup analysis, we conducted meta-re-
gression to detect possible sources of heterogeneity. Meta-regression
was performed for mean age. As reported in Fig. 5, there was strong
evidence that mean age was associated with variation in the estimates.
As it is clear from the slope of the line, as the slope increases (mean age)
Aspergillus coinfection rate increases. Mean age could significantly
explain the between-study heterogeneity β = −0.06, P = 0.00).
3.5. Findings of the correlation between pulmonary Aspergillus coinfection
with characteristics of precipitants and risk factors
As reported in Table 4, most of the studies included in the present
review showed the higher Aspergillus coinfection in the age group of 40
years and higher and the existence of a correlation between increasing
age and Aspergillus coinfection (p < 0.05). Also, five studies showed
the correlation between male genus and Aspergillus coinfection,
whereas, only one study showed this correlation with the female genus
Fig. 2. The Forest plot of the meta-analysis of the prevalence of pulmonary Aspergillus coinfection among patients with pulmonary tuberculosis.
Table 3
Overall effects of Aspergillus species in included studies.
Aspergillus species
Overall effects Number of studies Heterogeneity test Egger's test Random model
Prevalence (95% CI) (%) Z P Q P I2 T P
Aspergillus flavus 11 27.2 (19.3–36.7) 4.3 0.00 17.5 0.00 42.9 0.19 0.84
India 4 19.2 (10.8–31.7) 4.2 0.00 3.7 0.00 20 5.2 0.03
Iran 3 51.8 (15–86.8) 0.07 0.93 7.2 0.00 72.3 0.71 0.61
Aspergillus fumigatus 14 57.6 (40.1–73.3) 0.84 0.39 69.7 0.00 81.3 0.55 0.58
Aspergillus fumigatus (in India) 7 62.7 (30.3–86.6) 0.75 0.45 59.7 0.00 89.9 0.52 0.61
Aspergillus fumigatus (in Iran) 2 49.3 (16.4–82.8) 0.03 0.97 3.4 0.00 71.3 – –
Aspergillus niger 14 33.8 (28.8–39.3) 5.5 0.00 16.1 0.00 19.5 0.91 0.37
India 8 35 (29.3–41.2) 4.5 0.001 7.8 0.00 10.9 0.30 0.77
Iran 2 15.9 (6.1–35.7) 3 0.002 0.35 0.00 0.00 – –
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(p < 0.05). As well, no study reported the correlation between alcohol
consumption and Aspergillus coinfection. A study showed a higher
prevalence of pulmonary Aspergillus and Lower BMI. Also, three studies
presented the correlation between Aspergillus coinfection and smoking
(p < 0.05). Also, two studies reported the higher prevalence of pul-
monary Aspergillus coinfection and diabetes mellitus (underlying dis-
ease).
4. Discussion
In the present study, Aspergillus coinfection was varied between 3.7
and 33.3%. As well as, the combined prevalence of Aspergillus coin-
fection among patients with pulmonary tuberculosis was 15.4%. The
pooled prevalence of Aspergillus coinfection among patients with pul-
monary tuberculosis in Asia was 14.7% versus the combined prevalence
of Aspergillus coinfection in Africa (17.7%). Meat-regression results
revealed that with increasing mean age, Aspergillus coinfection rate
increased. Also, the most frequency of Aspergillus spp. was related to A.
fumigatus with a combined prevalence of 57.6%. The combined
Aspergillus coinfection reported from Kenya, Iraq, Nigeria, and Egypt
only was extracted from one study. However, the combined Aspergillus
coinfection of more than 15% was high, where this rate from Nigeria
was 80% and from Iraq, and Cameroon was over than 25%.
Interestingly, the pulmonary Aspergillus coinfection in Pulmonary TB+
patients was reported by 5.2% from Kenya.
This difference in reporting Aspergillus coinfection in Pulmonary
TB+ patients between different countries predominantly attributed to
the geographical location, health policies, climate conditions, and
socio-economic condition, phenotypic, duration of anti-tuberculosis
consumption by patients, clinical samples types, and molecular
methods used for detection of Aspergillus infections in each country
[18].
Most of the studies included in the present review showed the
higher Aspergillus coinfection in the age group of 40 years and higher
and the existence of a correlation between increasing age and
Aspergillus coinfection. Also, 5 out of 17 studies showed a correlation
Fig. 3. Funnel plot of meta-analysis on the prevalence of pulmonary Aspergillus coinfection among patients with pulmonary tuberculosis.
Fig. 4. Pooled prevalence of Aspergilus coinfection in pulmonary TB patients based on subgroup analysis (location and gender).
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between male genus and fungal coinfection, whereas, only one study
showed this correlation with the female genus (p < 0.05). It is referred
to this fact that the males are more vulnerable to infection than females
due to their greater exposure to the surrounding [19]. As well, the aged
patients over than 50 years, owing to the recurrent TB, the weakening
of the immune system, and also the prolonged anti-tubercular therapy,
becomes an effective predisposing factor for the beginning of coinfec-
tion by the fungal agents in active pulmonary tuberculosis [20].
Two studies conducted by Osman et al. [19], and Aldokree et al.
included in the current review indicated a correlation between DM and
fungal Aspergillus. Also, besides Osman and Aldokree, Mathavi et al.
[21] showed a correlation between pulmonary Aspergillus coinfection
and smoking. Similarly, Smoking and DM act as co-factors in quick-
ening and increasing the immune-suppression mode [22,23]. The pre-
valence of mycotic infection in diabetic patients has been confirmed by
Khanna et al. [24], they reported the main factors for prevalence of
Aspergillus in pulmonary tuberculosis as following; the existence of
resistant strains, the persistence of diseases, and underlying disease
including diabetes mellitus.
To our knowledge, eight countries (India followed by, China,
Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh and South
Africa) account for two thirds of the total TB cases, the 30 high TB
burden countries accounted for 87% of new TB cases [25]. Conse-
quently, given the high rate of tuberculosis in high TB burden countries,
the prevalence of Aspergillus coinfection is high. We showed that the
most frequency of Aspergillus spp. was related to A. fumigatus with a
combined prevalence of 57.6%. A. fumigatus can cause a variety of
pulmonary diseases such as aspergilloma that characterised by sapro-
phytic growth of the fungus in pre-existing tuberculous cavities [26].
Reports indicated a considerable worldwide burden of chronic pul-
monary aspergillosis as a sequel to PTB [6]. In regions with a high
occurrence of TB, criteria for the identification both CPA and tu-
berculosis are very identical that distinction between the two micro-
organisms is not possible, without serological tests for Aspergillus
Fig. 5. Meta-regression of mean age on prevalence of pulmonary Aspergillus coinfection among patients with pulmonary tuberculosis.
Table 4
The correlation between pulmonary fungal coinfection with characteristics of precipitants and risk factors.
Author Age (year) Genus Alcohol consumption BMI Smoking DM
Male Female
Shahid (2001) 45–65 – 1 – – – –
Kurhadi (2002) – – – – – – –
Bansod (2008) 35–44 Higher (correlation) No – – – –
Njunda (2012) 61–70 No correlation No correlation – – – –
Osman (2013) No correlation Higher (correlation) – – – Higher Higher
Nyambura Mwaura (2013) – – – – – – –
Jabbari Amiri (2015) – – – – – – –
Bhutia (2015) > 70 – Higher – – – –
Mathavi (2015) – – – No Low BMI(higher) Higher –
Yadu (2015) 50–59 -(64) – – – – –
Njunda (2015) 41–50 no no – – – –
Jabbari amiri (2016) – – – – – – –
Babita (2016) – – – – – – –
Astekar (2016) – – – – – – –
Aldorkee (2017) 31–40 Higher – – – Higher Higher
Jabbari Amiri (2018) 41–50 Higher (91) Higher – – – –
Bin Najeeb (2019) – – – – – – –
Note: The correlation related-data reported as narrative from studies included in the present review and no meta-analysis was done on them. DM: diabetes mellitus,
BMI: body mass index.
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antigens, even if the culture of samples (sputum, and etc) is positive for
A. fumigatus [6].
Despite the completion of the course of treatment for tuberculosis
by patients, secondary fungal infections had persistence of pulmonary
symptoms. Therefore, suitable measures should be taken for patients in
endemic areas for the potential of Co-infection and treated when
clinically indicated to identify and treat these infections promptly [21].
It needs that all fungi detected in clinical specimens from patients
especially immune-compromised and patients suffering from pul-
monary tuberculosis should be carefully identified and physicians
evaluate the clinical significance of these isolates in these patients [27].
Due to the importance of TB, should be paying more attention to the Co-
infection of tuberculosis with opportunistic fungi. Because of compar-
able clinical signs of tuberculosis and pulmonary fungal Co-infection, in
cases that direct smear and culture of samples for TB are negative, the
specimens were evaluated for opportunistic fungi.
Notably, most of the included studies have used phenotypic
methods to identify fungi except one case. Therefore, regarding the
importance of pulmonary Aspergillus coinfection, the use of molecular
methods and serological tests to identify Aspergillus coinfection is
needed. On the other hand, mycosis infection if diagnosed early can be
treated efficiently, and consequently can prevent from progress to fi-
brotic stage and avoided pulmonary disability [28]. Recognizing early
chronic pulmonary aspergillosis (CPA) in patients with residual pul-
monary shadows from pulmonary tuberculosis is only probable using
microbiological testing (principally for Aspergillus IgG antibodies). If
tests are not conducted, pulmonary mycoses can be easily misdiagnosed
and mistreated as pulmonary tuberculosis, which leads to inappropriate
therapy or none at all. In regions with a high occurrence of tuberculosis,
due to the high similarity of CPA and pulmonary tuberculosis between
them is not possible [6].
The limitations of this review are that, we only included the studies
published in the electronic databases; therefore, unpublished data were
missed from the present review. Second, this meta-analysis was per-
formed on a limited number of articles (n = 17), which may limit
statistical power for conducting a sufficient meta-analysis. Third, we
couldn't conduct subgroup analysis and meta-regression due to in-
sufficient data of Alcohol consumption, BMI, Participants (adults,
children, and neonates), smoking, DM, and ect. These factors may have
a significant effect on the variability of the estimates of prevalence.
Finally, the correlation related-data reported as narrative from studies
included in the present review and no meta-analysis was done owing to
insufficient data, too.
In summary, the present review showed the high combined
Aspergillus coinfection among patients with pulmonary tuberculosis in
high burden countries including India in Asia and African countries.
Also, amongst Aspergillus spp., the most frequency was related to A.
fumigatus. Thus, concerning the significance of pulmonary Aspergillus
coinfection, the role of fungal agents in exacerbation of tuberculosis
and the lack of improvement in tuberculosis symptoms such as chronic
cough, sputum or occasional hemoptysis following completion of anti-
tuberculosis chemotherapy, and miss diagnosis with tuberculosis, the
use of molecular methods and serological tests to identify Aspergillus
coinfection is necessary to early prevention from development to ad-
vanced fibrotic stage and avoided pulmonary disability [29]. Besides,
this study suggested that Aspergillus-coinfection is a frequent event in
patients who suffering from tuberculosis, so, the patients should be
regularly checked for problems resulted from Aspergillus.
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